Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IMPORTANCE: Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits atte...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA
Autores principales: You, Seng Chan, Rho, Yeunsook, Bikdeli, Behnood, Kim, Jiwoo, Siapos, Anastasios, Weaver, James, Londhe, Ajit, Cho, Jaehyeong, Park, Jimyung, Schuemie, Martijn, Suchard, Marc A., Madigan, David, Hripcsak, George, Gupta, Aakriti, Reich, Christian G., Ryan, Patrick B., Park, Rae Woong, Krumholz, Harlan M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7592033/
https://ncbi.nlm.nih.gov/pubmed/33107944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.16167
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares